Routine and interval detection of locoregional breast cancer recurrences and risk of subsequent distant metastasis

Author:

Eijkelboom Anouk H.ORCID,de Munck Linda,de Vries Maaike,Francken Anne Brecht,Hendriks Mathijs P.,Strobbe Luc,Witteveen Annemieke,van Maaren Marissa C.,Siesling Sabine

Abstract

Abstract Purpose Follow-up for breast cancer survivors consists of after care and surveillance. The benefits of routine surveillance visits remain debatable. In this study we compared the severity of locoregional recurrences (LRRs) and the subsequent risk of a distant metastasis (DM) between LRRs detected at routine and interval visits. Methods Women diagnosed with early breast cancer between 2003 and 2008 in one of the 15 participating hospitals, and who developed a LRR as first event after primary treatment, were selected from the Netherlands Cancer Registry (Cohort A). Chi-squared tests were used to compare the severity of routine- and interval-detected local recurrences (LRs) and regional recurrences (RRs), using tumor size, tumor grade, and number of positive lymph nodes. Data on the development of a subsequent DM after a LRR were available for a subset of patients (Cohort B). Cohort B was used to estimate the association between way of LRR-detection and risk of a DM. Results Cohort A consisted of 109 routine- and 113 interval-LRR patients. The severity of routine-detected LRs or RRs and interval-detected LRs or RRs did not significantly differ. Cohort B consisted of 66 routine- and 61 interval-LRR patients. Sixteen routine- (24%) and 17 (28%) interval-LRR patients developed a DM. After adjustment, way of LRR-detection was not significantly associated with the risk of a DM (hazard ratio: 1.22; 95% confidence interval: 0.49–3.06). Conclusion The current study showed that routine visits did not lead to less severe LRRs and did not decrease the risk of a subsequent DM.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Reference37 articles.

1. World Cancer Research Fund, American Institute for Cancer Research (2018) Worldwide cancer data, Global cancer statistics for the most common cancers. https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data. Accessed 11 Nov 2021

2. van der Meer DJ, Kramer I, van Maaren MC, van Diest PJ, Linn SC, Maduro JH, Strobbe LJA, Siesling S, Schmidt MK, Voogd AC (2020) Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in the Netherlands between 1989 and 2017. Int J Cancer 148:2289–2303. https://doi.org/10.1002/ijc.33417

3. National GAU (2018) Early and locally advanced breast cancer: diagnosis and management. https://www.nice.org.uk/guidance/ng101. Accessed 10 Dec 2021

4. Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE (2013) Breast cancer follow-up and management after primary treatment: American Society of clinical oncology clinical practice guideline update. J Clin Oncol 31:961–965. https://doi.org/10.1200/JCO.2012.45.9859

5. Comprehensive Cancer Organisation the Netherlands (IKNL) (2020) Detectie nieuwe carcinoommanifestaties. https://www.oncoline.nl/borstkanker. Accessed 13 Feb 2020

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3